Bonus Biogroup Ltd.

F-1/A amended

Bonus Biogroup Ltd. is conducting its initial public offering (IPO) in the U.S., offering 3,750,000 American Depositary Shares (ADSs) representing 112,500,000 ordinary shares. The offering price is estimated between $4.00 and $6.00 per ADS, with the ADSs pending listing on Nasdaq under the symbol BONS. The company aims to raise capital for research and development, with a focus on tissue engineering and cell therapy products like BonoFill and MesenCure. The filing includes updated financial disclosures and underwriting terms compared to prior amendments.

F-1/A amended

Bonus Biogroup Ltd. is conducting its initial public offering (IPO) in the U.S., offering 3,000,000 American Depositary Shares (ADSs) representing 90,000,000 ordinary shares. The ADSs are priced between $4.00 and $6.00 each, with the company seeking Nasdaq listing under the symbol BONS. The offering includes underwriter options for additional shares and warrants. The company focuses on tissue engineering and cell therapy products, including BonoFill and MesenCure, targeting unmet clinical needs. It is an emerging growth company with risks related to product development, regulatory approval, and market competition.

F-1/A amended

Bonus Biogroup Ltd. is conducting its initial public offering (IPO) in the U.S., offering American Depositary Shares (ADSs) representing ordinary shares. The company aims to list ADSs on Nasdaq under the symbol BONS, contingent on approval. The IPO involves a clinical-stage biotechnology focus on tissue engineering and cell therapy products, including BonoFill and MesenCure. The offering includes underwriting terms with a 45-day option for the underwriter to purchase additional ADSs, compared to 30 days in the previous filing.

FWP supplemental

F-1/A amended

Bonus Biogroup Ltd. has filed an amended F-1/A registration statement for its U.S. IPO, updating details around the American Depositary Shares (ADS) offering. The filing includes finalized pricing terms, underwriting arrangements, and proceeds, alongside enhanced disclosures on product candidates BonoFill and MesenCure. The company emphasizes its focus on tissue engineering and cell therapies, with BonoFill targeting bone regeneration and MesenCure addressing inflammation. The filing also highlights regulatory risks and dependency on clinical trial outcomes.

F-1 filed

Bonus Biogroup Ltd. is conducting its initial public offering (IPO) in the U.S., offering American Depositary Shares (ADSs) representing ordinary shares. The company, a clinical-stage biotechnology firm, focuses on developing tissue engineering and cell therapy products, including BonoFill for bone regeneration and MesenCure for inflammation and tissue damage. The offering is contingent on Nasdaq listing, with an estimated price range and underwriting terms including warrants and expense reimbursements. The company operates as an emerging growth company and a foreign private issuer, with financial statements prepared under IFRS.

DRS/A amended

Bonus Biogroup Ltd. filed an amended registration statement (DRS/A) on April 10, 2025, updating its initial public offering (IPO) details. The filing includes audited financial statements for the full year 2024, compared to the previous DRS filing which included unaudited nine-month data for 2024. The company aims to list American Depositary Shares (ADSs) on Nasdaq under the symbol BONS, with an estimated offering price range. Key product candidates, BonoFill and MesenCure, remain central to the offering, targeting bone regeneration and inflammatory disease treatments.

DRS filed

Bonus Biogroup Ltd. is a clinical-stage biotechnology company focused on developing next-generation tissue engineering and cell therapy products. The company is conducting its initial public offering (IPO) in the U.S., proposing to list American Depositary Shares (ADSs) on the Nasdaq Capital Market under the symbol BONS. The offering includes two product candidates: BonoFill, a personalized autologous bone graft, and MesenCure, an allogeneic cell therapy for inflammation and tissue damage. The filing highlights the company's status as an emerging growth company and a foreign private issuer, with financial statements prepared under IFRS. A reverse share split was effectuated on February 27, 2025, and the offering is contingent on Nasdaq listing approval.